Lomustine

Generic Name: Lomustine

Brand Names: Ceenu, Gleostine

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₆ClN_₃O_₂

CAS Number: 13010-47-4

Unique Ingredient Identifier: 7BRF0Z81KG

Background: An alkylating agent of value against both hematologic malignancies and solid tumors.

Indication: For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.

Associated Conditions: Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma

Clinical Trials

Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients

Phase 2

Conditions: GBM

Interventions: Drug: Chlorogenic acid for Injection
Drug: Lomustine

First Posted Date: 2018-11-29

Last Posted Date: 2018-11-29

Lead Sponsor: Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd

Target Recruit Count: 200

Registration Number: NCT03758014

Locations: 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China

9-ING-41 in Patients with Advanced Cancers

Phase 2

Active, not recruiting

Conditions: Cancer
Pancreatic Cancer
Pancreatic Adenocarcinoma
Neoplasm, Breast
Neoplasms Pancreatic
Malignancies
Malignancies Multiple
Bone Cancer
Pancreatic Neoplasms
Neoplasm Metastasis

Interventions: Drug: 9-ING-41
Drug: Gemcitabine - 21 day cycle
Drug: Nab paclitaxel.
Drug: Doxorubicin.
Drug: Carboplatin.
Drug: Lomustine
Drug: Irinotecan
Drug: Gemcitabine - 28 day cycle
Drug: Paclitaxel.

First Posted Date: 2018-09-20

Last Posted Date: 2024-11-07

Lead Sponsor: Actuate Therapeutics Inc.

Target Recruit Count: 350

Registration Number: NCT03678883

Locations: 🇪🇸
Institut Catala d'Oncologia, Barcelona, Spain
🇪🇸
Hospital Clinico U San Carlos (HSC), Madrid, Spain
🇪🇸
START Madrid-HM CIOCC Hospital Universitario, Madrid, Spain

and more 62 locations

Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Phase 2

Completed

Conditions: High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma

Interventions: Drug: nab-sirolimus
Drug: nab-sirolimus + temozolomide
Drug: nab-sirolimus + bevacizumab
Drug: nab-sirolimus + lomustine
Drug: nab-sirolimus + marizomib (MRZ)
Drug: nab-sirolimus + temozolomide + radiotherapy

First Posted Date: 2018-03-13

Last Posted Date: 2023-11-07

Lead Sponsor: Aadi Bioscience, Inc.

Target Recruit Count: 62

Registration Number: NCT03463265

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
St. Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Phase 1

Completed

Conditions: Newly Diagnosed High Grade Glioma

Interventions: Drug: Nivolumab monotherapy
Drug: Temozolomide
Drug: Nivolumab
Radiation: conformal brain radiation therapy
Drug: Ipilimumab
Drug: 5-day Temozolomide
Drug: Bevacizumab
Drug: Lomustine

First Posted Date: 2018-02-07

Last Posted Date: 2023-11-08

Lead Sponsor: Saint John's Cancer Institute

Target Recruit Count: 49

Registration Number: NCT03425292

Locations: 🇺🇸
Saint John's Cancer Institute, Santa Monica, California, United States

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Phase 1

Recruiting

Conditions: Glioblastoma Multiforme

Interventions: Biological: VBI-1901
Drug: Carmustine
Drug: Lomustine

First Posted Date: 2017-12-26

Last Posted Date: 2025-03-11

Lead Sponsor: VBI Vaccines Inc.

Target Recruit Count: 98

Registration Number: NCT03382977

Locations: 🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸
University of California, Los Angeles Neuro-Oncology Program, Los Angeles, California, United States

and more 9 locations

VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM

Phase 3

Terminated

Conditions: Glioblastoma Multiforme
Glioma
GBM
Brain Cancer
Glioblastoma

Interventions: Drug: Physician's Choice of Salvage Therapy - temozolomide
Drug: VAL-083, Dianhydrogalactitol
Drug: Physician's Choice of Salvage Therapy - lomustine
Drug: Physician's Choice of Salvage Therapy - carboplatin

First Posted Date: 2017-05-11

Last Posted Date: 2023-11-22

Lead Sponsor: DelMar Pharmaceuticals, Inc.

Target Recruit Count: 2

Registration Number: NCT03149575

Locations: 🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
University of California, San Francisco - Division of Neuro-Oncology, San Francisco, California, United States

and more 2 locations

A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme

Phase 2

Conditions: Glioblastoma
GBM
Recurrent Brain Tumor
Glioblastoma Multiforme
Glioblastoma, Adult

Interventions: Drug: Lomustine
Drug: Sunitinib

First Posted Date: 2017-01-20

Last Posted Date: 2021-04-19

Lead Sponsor: Amsterdam UMC, location VUmc

Target Recruit Count: 100

Registration Number: NCT03025893

Locations: 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
🇳🇱
Radboud UMC, Nijmegen, Netherlands
🇳🇱
University Medical Center Groningen, Groningen, Netherlands

Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Phase 2

Terminated

Conditions: IDH Family Wildtype
Recurrent Anaplastic Astrocytoma
Recurrent Glioblastoma

Interventions: Procedure: Laser Interstitial Thermal Therapy
Drug: Lomustine

First Posted Date: 2017-01-16

Last Posted Date: 2022-08-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT03022578

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Regorafenib in Relapsed Glioblastoma

Phase 2

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: Lomustine
Drug: Regorafenib

First Posted Date: 2016-10-06

Last Posted Date: 2022-09-09

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 119

Registration Number: NCT02926222

Locations: 🇮🇹
IRCCS "Saverio de Bellis, Castellana Grotte, BA, Italy
🇮🇹
Azienda Ospedaliera "G.Rummo", Benevento, BR, Italy
🇮🇹
istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori, Cesena, FC, Italy

and more 7 locations

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

Phase 3

Conditions: Anaplastic Astrocytoma
Recurrent Anaplastic Astrocytoma

Interventions: Drug: Eflornithine
Drug: Lomustine

First Posted Date: 2016-06-10

Last Posted Date: 2022-01-21

Lead Sponsor: Orbus Therapeutics, Inc.

Target Recruit Count: 343

Registration Number: NCT02796261

Locations: 🇨🇦
Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada
🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre Georges François Leclerc, Dijon, France

and more 75 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy